Evidence map›Paper›PMID 40671689›Full record

ArticleInternational journal of nanomedicine2025

DS-Modified Paeoniflorin pH-Responsive Lipid-Polymer Hybrid Nanoparticles for Targeted Macrophage Polarization in a Rat Model of Rheumatoid Arthritis.

Junhao Zhang, Jing Yang, Zhoubo Yu, Haotian Bai, Yanhong Wang, Rui Wang

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junhao Zhang *College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.
Jing Yang *Basic Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.
Zhoubo YuCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.
Haotian BaiCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.
Yanhong WangCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.ORCID 0000-0003-2092-2400
Rui WangCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Macrophages play a pivotal role in rheumatoid arthritis (RA) pathogenesis. Paeoniflorin, a traditional Chinese medication, reduces inflammation by suppressing immune cell activation and inducing synovial fibroblast apoptosis, attenuating RA disease progression. Despite the potential therapeutic benefits, free paeoniflorin has limitations, including low drug utilization, poor selectivity, and short half-life during administration. We aimed to develop and evaluate dextran sulfate-modified paeoniflorin pH-responsive lipid-polymer hybrid nanoparticles (Pae-PPNPs-DS) for targeted macrophage delivery and improved treatment efficacy in RA. The pH sensitivity is attributed to the incorporation of poly(cyclohexane-1,4-dimethylene ketal), which undergoes hydrolysis-triggered degradation under acidic conditions enabling passive targeting to inflammatory sites through pH-dependent drug release. Simultaneously, dextran sulfate serves as a ligand to actively target Scavenger receptor class A type I overexpressed on activated macrophages in RA synovium, achieving dual-targeted delivery via environmental responsiveness and ligand-receptor interaction. Methods: We developed dextran sulfate-modified Pae-PPNPs-DS, which exhibits dual capabilities of active macrophage targeting and pH-triggered drug release, to deliver paeoniflorin to macrophages and improve drug delivery at the joint inflammation site. Nanoparticle characterization, in vitro release behavior, stability, macrophage uptake, macrophage polarization pathway, phenotypic polarization, and therapeutic efficacy were evaluated in a rat model of RA. Results: Pae-PPNPs-DS had smooth surfaces, uniform particle sizes, physical stability, and pH-responsive characteristics. RAW264.7 macrophages showed enhanced Pae-PPNPs-DS uptake. Pae-PPNPs-DS effectively modulated the STAT signaling pathway and modulated macrophage polarization. Pae-PPNPs-DS inhibited the expression of Conclusion: Pae-PPNPs-DS actively target macrophages, regulate polarization through STAT pathway, and inhibit joint inflammation, suggesting its potential in treating RA. The study highlights the potential of pH-responsive nanocarriers as an innovative approach to treating autoimmune diseases.

Indexed as

Arthritis, RheumatoidGlucosidesMacrophagesMonoterpenesNanoparticlesAnimalsDextran SulfateDisease Models, AnimalDrug CarriersDrug LiberationGlycosidesHydrogen-Ion ConcentrationLipidsMaleMicePolymersDextran SulfateDrug CarriersGlucosidesGlycosidesLipidsMonoterpenespeoniflorinPolymersCIA modelhybrid nanoparticlesmacrophage targetingpH-responsive drug deliverytargeted therapy

Identifiers

PMID40671689
PMCPMC12266063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.